期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

临床常用抗骨质疏松药物 被引量：4

Commonly used anti-osteoporosis drugs in clinic
下载PDF
导出
摘要 临床常用的抗骨质疏松药物种类很多,各有不同的特点。本文简述各类抗骨质疏松药物的作用机制、作用特点和不良反应。 There are a variety of commonly used anti-osteoporosis drugs in clinic, which have different characteristics. This paper reviews their mechanisms of actions, characteristics of roles and adverse reactions.
作者 谭雯 吴晞
机构地区 复旦大学附属华东医院内分泌科 复旦大学附属华山医院内分泌科
出处 《上海医药》 CAS 2013年第9期6-9,共4页 Shanghai Medical & Pharmaceutical Journal
关键词 骨质疏松症 激素替代疗法 选择性雌激素受体调节剂 双膦酸盐类药物 降钙素 甲状旁腺激素 维 生素D osteoporosis hormone replacement therapy selective estrogen receptor modulators bisphosphonates calcitonin parathyroid hormone vitamin D
分类号 R580 [医药卫生—内分泌]
  • 相关文献

参考文献23

  • 1Caufriez A. Hormonal replacement therapy (HRT) in postmenopause: a reappraisal [J]. Ann Endocrinol (Paris), 2007, 68(4): 241-250.
  • 2Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin [J]. Maturitas, 2006, 55(2): 103-115.
  • 3Burger HG, MacLennan AH, Huang KE, et al. Evidence- based assessment of the impact of the WHI on women's health [J]. Climacteric, 2012, 15(3): 281-287.
  • 4Cheng MH, Chen JF, Fuh JL, et al. Osteoporosis treatment in postmenopausal women with pre-existing fracture [J]. Taiwan J Obstet Gynecol, 2012, 51(2): 153-166.
  • 5Qu Y, Wong M, Thiebaud D, et al. The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial [J]. Curr Med Res Opin, 2005, 21(12): 1955-1959.
  • 6Duvernoy CS, Kulkarni PM, Dowsett SA, et al. Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: incidence, patient characteristics, and effect of raloxifene [J]. Menopause, 2005, 12(4): 444-452.
  • 7McClung M, Harris ST, Miller PD, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday [J]. Am J Med, 2013, 126(1): 13-20.
  • 8Felsenberg D, Alenfeld F, Bock O, et al. Placebo-controlled multicenter study of oral alendronate in postmenopausal osteoporotic women. FOSIT-Study-Group. Fosamax International Trial [J]. Maturitas, 1998, 31(1): 35-44.
  • 9Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group [J]. J Clin Endocrinol Metab, 2000, 85(11): 4118-4124.
  • 10Hosking D, Adami S, Felsenberg D, et al. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study [J]. Curr Med Res Opin, 2003, 19(5): 383-394.

同被引文献45

引证文献4

二级引证文献13

上海医药
2013年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部